[PDF][PDF] KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Lung squamous cell carcinoma (LUSC) represents a major subtype of lung cancer with
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …
[HTML][HTML] FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression
The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of
intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) …
intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) …
[HTML][HTML] Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
Background Small cell lung cancer (SCLC) is a deadly disease with a 5-year survival of less
than 7%. The addition of immunotherapy to chemotherapy was recently approved as first …
than 7%. The addition of immunotherapy to chemotherapy was recently approved as first …
[HTML][HTML] Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC
H Zhang, CS Nabel, D Li, RÍ O'Connor… - Journal of Thoracic …, 2023 - Elsevier
Abstract Introduction In KRAS-mutant NSCLC, co-occurring alterations in LKB1 confer a
negative prognosis compared with other mutations such as TP53. LKB1 is a tumor …
negative prognosis compared with other mutations such as TP53. LKB1 is a tumor …